


### PHARMACEUTICAL 2017



# Xenon Pharmaceuticals Inc. Rank 24 of 292





#### PHARMACEUTICAL 2017



## X XENON

## Xenon Pharmaceuticals Inc. Rank 24 of 292

The relative strengths and weaknesses of Xenon Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Xenon Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 94% points. The greatest weakness of Xenon Pharmaceuticals Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 245%, being 242% points above the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	65,675
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,516
Liabilities, Non-Current	0
Other Assets	408
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	70
Other Net Income	1,820
Other Revenues	1,803
Property and Equipment	1,404
Research and Development	19,828
Selling, General and Administrative Expense	6,792

Output Variable	Value in 1000 USD
Assets	67,487
Liabilities	3,586
Expenses	26,620
Revenues	1,803
Stockholders Equity	63,901
Net Income	-22,997
Comprehensive Net Income	-22,997
Economic Capital Ratio	245%